1

Titan Medical Inc.

Annual General Meeting

TSX: TMD | OTCQX: TITXF

June 9, 2015

2

This presentation contains "forward-looking statements" which reflect the current expectations of management of the

Company's future growth, results of operations, technological development and implementation, performance and

business prospects, opportunities, and illustrations and prototypes of the SPORT Surgical Systems. Wherever possible,

words such as "may", "would", "could", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate" and similar

expressions have been used to identify these forward-looking statements. These statements reflect management's

current beliefs with respect to future events and are based on information currently available to management.

Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the

Company's actual results, performance, achievements or technological development and implementation to be

materially different from any future results, performance, achievements or technological development and

implementation that may be expressed or implied by such forward-looking statements, including, without limitation,

those listed in the "Risk Factors" section of the Company's Annual Information Form dated April 4, 2014 and other

information contained in the Companys public filings (which may be viewed at www.sedar.com). Information contained

in this presentation is qualified in its entirety by such public filings. Should one or more of these risks or uncertainties

materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results,

performance or achievements may vary materially from those expressed or implied by the forward-looking statements

contained in this presentation. These factors should be considered carefully and prospective investors should not place

undue reliance on the forward-looking statements. Although the forward-looking statements contained in the

presentation are based upon what management currently believes to be reasonable assumptions, the Company cannot

assure prospective investors that actual results, performance or achievements will be consistent with these forward-

looking statements. This presentation does not constitute an offer to sell any class of securities of the Company in any

jurisdiction.

Forward Looking Statements

3

2014 Ranking

The 2015 OTCQX Best 50 is a ranking of top performing companies on the

OTCQX Best Marketplace in 2014 based on one-year share price performance

and average daily dollar volume growth.

Source: http://www.otcmarkets.com/content/doc/2015-OTCQX-Best-50.pdf

4

March 31, 2015

Share Price (TMD)

$1.43

Cash, cash equivalents and

short-term investments

$27.4 million

Shares outstanding 102.6 million (105.2 million FD*)

Market value 146.7 million ($150.5 million FD*)

Management ownership (March 31, 2015)

6.21%

*Fully diluted includes, under the Treasury Stock method, an additional 2,224,604 options with a weighted-average exercise price of CDN $1.14. In addition, 3,665,900 warrants (@CDN $1.85 expiring December 10, 2015), 5,121,500 warrants (@CDN $2.00 expiring June 21, 2016), 3,484,500 warrants (@CDN $1.75 expiring December 22, 2016), 390,729 warrants (@CDN $1.77 expiring March 14, 2017), 5,300,705 warrants (@CDN $1.25 expiring March 13, 2018), 8,317,856 warrants (@CDN $2.00 expiring February 19, 2017), and an additional 12,346,914 warrants (@CDN $2.75 expiring April 23, 2017).

Financial Snapshot

TMD (TSX), TITXF (OTCQX)

(in US Dollars except warrants and options exercisable in Canadian dollars)

March 31, 2014

Share Price (TMD)

$1.97

Cash, cash equivalents and short-term investments

$15.6 million

Shares outstanding 84.5 million (91.1 million FD*)

Market value 166.5 million ($179.4 million FD*)

Management ownership

(March 31, 2014) 7.39%

5

Stock performance

$0.00

$50.00

$100.00

$150.00

$200.00

$250.00

$300.00

$350.00

$400.00

2009 2010 2011 2012 2013 2014

Titan Medical Inc. - Common Share Price Performance

Titan Medical Inc.

S&P/TSX Composite Index

As at December 31

31-Dec-09 31-Dec-10 31-Dec-11 31-Dec-12 31-Dec-13 31-Dec-14

Titan Medical Inc. 100.00 355.00 337.50 300.00 237.50 350.00

S&P/TSX Composite Index 100.00 114.45 101.78 105.85 115.97 124.57

The following table shows the value of CDN$100 invested in Common Shares on December 31, 2009 compared to CDN$100 invested in

the S&P/TSX Composite Index*:

*All amounts in Canadian $.

6

Based on current customer challenges:

Problems in delivery of high-quality outcomes

Issues that de-motivate staff

Workflow inefficiencies which increase costs, and

Anything that would diminish patient outcomes

Value-Based Account Management

A NEW GAME IN TOWN

7

Capital equipment downtime/utilization

Surgical scheduling and procedural planning

Opportunities for surgical indications of general abdominal, gynecologic and urologic procedures

Staff morale

Increased patient wait time

Patient satisfaction scores

Staff retention and optimization

Workflow

Capacity

Revenues

Current Challenges

Clinical Financial Operational

8

Builds trust in the customer relationship

Evolves the sales team from the feature-function product approach to value-based Account Management at its best

Fosters problem solving and trust with customers

Guides customers to find Clinical, Financial and Operational Mission-aligned solutions, and

Finally Assists the customer to monetize and thereby designate the value of the robotic solution

Value-Based Account Management Deliverables

9

1. GPOs

2. IDNs

3. Acute care hospitals

4. Health systems

5. Academic medical centers

6. Ambulatory care centers

7. DOD/VA Hospitals

8. Professional Healthcare Organizations

9. Large healthcare insurers

10. CMS (Center of Medicare Services)

11. American Hospital Association

12. Surgeons in North America, Europe and ROW

Voice of Customer/Industry Sources

10

The playing field

Capital Expense is $2 to $2.5 million

Service Fees are $170K to 10% of unit purchase price

Hospital spend is $1000 to $4000 more per robotic case than laparoscopic or open procedures

The game

Growth from 1000 procedures in 2000 to 570,000 in 2014

Growth potential is 4 million procedures

Estimated 3266 daVinci systems being used worldwide 2014

2223 systems in United States

1043 systems in ROW, including 21 systems in Canada

Total revenue in 2014 was $2.1 Billion

70% in United States ($1.47 Billion)

Sport Scouting Report

Sources: Intuitive Surgical Inc. Annual Report; General Surgery News Doing the Math: Can the Robot Be Cost Effective for General Surgery?

11

1. A balance of expertise and skills

2. Ability to build value

a. Scientific discovery

b. Solid planning

3. Capacity to Strategically Work with the right partners

4. Ability to adapt with the changing environment

5. A solid track record

A great technology needs the right team and the right management

Titan Management Team Assessment

12

Titan Medical Inc.

AGM Technology, Training, Regulatory Update

13

The SPORT Surgical System

14

THE SPORT SURGICAL SYSTEM

Technology Development Strategy

15

Focused on meeting the Customers Needs

Capital cost too expensive

Cost per case too high

Lack of mobility reduces operational efficiency

Return on investment not realized in many programs

Efficiency color coding instruments, etc.

Training programs need improvement

Customer support and service

Data collection and analytics

Titan Medical Inc. Strategy

16

The SPORT Surgical System delivers

Next Generation Surgical Robotic Technology

Innovative Robotic Platform to Enable Computer-assisted surgery

Automation and Navigation

Automate tasks and subtasks

The SPORT Surgical System is NOT

Just a teleoperation device

Just a single port device

THE SPORT Surgical System

17

THE SPORT SURGICAL SYSTEM

Technology Update

18

THE SPORT Surgical System

Traditional Surgical Robotic Features

Teleoperation

3-Dimensional (Stereoscopic) Imaging

Restores intuitive control

Enhanced or New Functionality

Enhanced Ergonomics

19

State of the Art 3D High Definition 32 display

Improved Dexterity

Outstanding Controllability

Information Delivery 2nd Display

Automated functionality

Data collection and analytics

For surgeon

For OR Team

Enhanced Functionality/Features

20

More comfortable working position

More comfortable, adjustable

seat Elbow Support not Forearm

Support

Familiar Flat Panel Immersive Interface

Touch Panel GUI

Familiar

Improved Ergonomics

The machine adapts to the surgeon instead of the surgeon adapting to the machine.

21

Two Major Components

CAD Renderings of SPORT Surgical System

The SPORT Surgical System

Patient Cart Surgeon Workstation

22

The surgeon interface at which the surgeon sits

3D High Definition Display

2nd Display Information Delivery

2 master controllers

Foot pedals

Surgeon Workstation

CAD Rendering of SPORT Surgical System

23

Looks-Like Workstation

24

Looks-Like Workstation

25

Looks-Like Workstation

26

Looks-Like Workstation

27

Rolling Cart at Bedside

Mast and Boom

Central Unit

Insertion Tube

Camera Module

Insertable Robotic Arms

Tools

Patient Cart

28

Patient Cart

29

Central Unit

Motors Connections for

Insertion Tube Instruments

30

Camera Module and Robotic Arms

19 mm Diameter Insertion Tube

Stereoscopic Camera Module

Pan and Tilt

Digital Zoom

Two Snake-Like Robotic Arms

Tools

31

Single-Patient Use Tool Tips

Sterile

No Reprocessing Required

First Use Quality Every Case

Reposable Robotic Arms

More Cases for Each Arm

Reduces per Case Cost

Tools

32

THE SPORT SURGICAL SYSTEM

Training Update

33

We believe that adults learn best from experience

But you cant just throw a simulator at them

Pyramid of Learning Experiences

Teach others

Discussion group

Demonstration

Audiovisual

Reading

Practice by doing

5%

10%

20%

30%

50%

75%

80%

Average

Retention Rate

National Training Laboratories, Bethel, Maine, USA

Lecture

34

Training Curriculum

Cognitive pre-training Knowledge Acquisition

Psychomotor skills training Technical Skills Acquisition

Team training Choreography & Communication

Troubleshooting Crisis Mitigation

Overview of safety Optimal Skills and Teamwork

The SPORT Surgical System

35

Training Curriculum

Cognitive pre-training

Knowledge Acquisition

Psychomotor skills training

Technical Skills Acquisition

Team training Choreography & Communication

Troubleshooting Crisis Mitigation

Overview of safety Optimal Skills and Teamwork

SAIL Center James and Sylvia Earl Simulation to Advance Innovation and Learning Center

Post-Training Assessment

Design assessment tools

Define: skills, setting, scoring method, scenarios, & train raters

Validate assessment tools

Construct Validity, Predictive Validity

Learning Experiences

Assessment Tools

36

THE SPORT SURGICAL SYSTEM

Regulatory Update

37

Regulatory Update

All Regulatory Processes are based on the Development Timeline

FDA

CE Mark

Notified Body

QMS

38

Key Milestones

1Q 2015

4Q 2015

3Q 2016

Mid-2017 4Q 2016

U.S. Commercial

Launch (Pending 510(k)

Market Clearance)

Pivotal Trial Completed, 510(k) Submitted to FDA

O.U.S. Commercial

Launch (Pending CE Mark Approval)

Design and

Test of Feasibility Prototype Completed 2Q 2016

Pivotal Human

Clinical Trial Commenced

Early Human Feasibility Report

Completed

Audit for CE Mark Commenced

Units Built and

Ready for Engineering Verification

39

Pre-submission meetings Next 9 months

Animal Study

Software Validation

Pivotal Clinical Trial

Symposium July 2015

Titan Participating

Early Feasibility Human Trial

Contract Research Organization

Regulatory Update FDA

40

CE Mark

Notified Body Summer 2015

Quality Management System

Processes Implemented

Standard Operating Protocols

Technical Files

Electronic Documentation and Infrastructure (August 2015)